Page 22 - Epic Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Working against this dynamic market are the f...

Truvian raises $105M, plans to submit benchtop blood-testing tech to FDA Benchtop blood testing startup Truvian raised $105 million in series C funding, which it plans to use to pave the way to submit its device for FDA clearance. Shares0 Truvian Sciences plans to seek FDA clearance and CLIA certification for its benchtop blood testing device. Photo credit: Truvian Sciences Truvian Sciences, a startup building a benchtop blood analyzer, raised $105 million in funding. The San Diego-based company plans to use the funds to seek 510(k) clearance and a CLIA waiver from the Food and Drug Administ...

Exact Sciences Announces Fourth Quarter 2020 Results News provided by Share this article Share this article MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. "Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because of the pandemic," said Kevin Conroy, chairman and CEO of Exact Sciences. "We are a leader in cancer...

Global Proteomics Partnering Terms and Agreements Analysis Report 2020 News provided by Share this article Share this article ResearchAndMarkets.com's offering. The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option ri...

Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market. Learn all about how diagnostic players are jockeying for position with their pha...